Abstract Number: 446 • 2012 ACR/ARHP Annual Meeting
Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Rheumatoid Arthritis Patients
Background/Purpose: Although there is much discussion regarding when to initiate a biological agent in rheumatoid arthritis (RA) patients, data on when to stop these agents…Abstract Number: 2540 • 2012 ACR/ARHP Annual Meeting
Prescription of Tumour Necrosis Factor α Antagonists Is Strongly Associated with a Reduction in Hospital Admissions and in Musculoskeletal Surgical Procedures for Rheumatoid Arthritis Based On a 16 Year Analysis of Nationwide Data
Background/Purpose: Comorbidities, joint destruction leading to orthopaedic intervention and physical disability are predictable outcomes of uncontrolled Rheumatoid Arthritis (RA). Synthetic DMARDS have a slow mechanism…Abstract Number: 1844 • 2012 ACR/ARHP Annual Meeting
Inequities in Access to Biologic Disease-Modifying Anti-Rheumatic Drugs for Patients with Rheumatoid Arthritis Across 46 European Countries
Background/Purpose: In the treatment of patients with RA, EULAR recommends to initiate biologic DMARDs after failing synthetic DMARDs. However, biologics are costly, and it is…Abstract Number: 1271 • 2012 ACR/ARHP Annual Meeting
Two-Year Drug Survival and Treatment Effect of Abatacept and Tocilizumab in the Treatment of Rheumatoid Arthritis in Routine Care. Results From the Nationwide Danish Danbio Registry
Background/Purpose: Abatacept and tocilizumab have been shown to be efficacious for the treatment of rheumatoid arthritis (RA), even in patients refractory to tumor necrosis factor…Abstract Number: 448 • 2012 ACR/ARHP Annual Meeting
Sustained and Cumulated Response Over Time in Rheumatoid Arthritis Patients Treated with Rituximab After Initial Failure of Anti Tumor Necrosis Factor Agents
Background/Purpose: Although anti-TNF therapies moved forward the treatment of rheumatoid arthritis (RA), failure of the first anti-TNF medication is not uncommon. Many times modifying dosage/frequency…Abstract Number: 2525 • 2012 ACR/ARHP Annual Meeting
Bruton’s Tyrosine Kinase Inhibition Suppresses Inflammatory Cytokine Production and Affects Gene Expression in Human Macrophages and RA Synovial Tissue Explants
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and progressive autoinflammatory disorder characterized by the infiltration of inflammatory cells, including B-cells, T-cells and macrophages, in the…Abstract Number: 1845 • 2012 ACR/ARHP Annual Meeting
Inequalities Across 46 European Countries in Clinical Eligibility Criteria for the Start of A First (Reimbursed) Biologic in Patients with Rheumatoid Arthritis
Background/Purpose: In the treatment of patients with RA, strategies that include biologics have resulted in a better outcome for patients with regard to disease activity,…Abstract Number: 1204 • 2012 ACR/ARHP Annual Meeting
Porphyromonas Gingivalis Antibody Responses and Clinical Associations in Patients with Early Rheumatoid Arthritis
Background/Purpose: Three prior studies have demonstrated an increased frequency of antibody responses to P. gingivalis (Pg), a leading agent of periodontal disease (PD), in RA…Abstract Number: 449 • 2012 ACR/ARHP Annual Meeting
Rituximab After First Anti Tumor Necrosis Factor Failure Is More Efficient with High Impact in Reducing Time and Costs to Achieve Superior Rates of Low Disease Activity and Remission
Background/Purpose: Significant steps were done in creating new medications for treatment of rheumatoid arthritis (RA). As RA seriously affects the patients’ quality of life, the…Abstract Number: 2485 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor: Analyses of Efficacy and Safety of 10 versus 5mg Twice Daily in a Pooled Phase 3 and Long-Term Extension Rheumatoid Arthritis Population
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. Phase (P) 3 studies demonstrated…Abstract Number: 1827 • 2012 ACR/ARHP Annual Meeting
Factors That Impact Work Productivity in the Preserve Trial: A Randomized Controlled Trial of Combination Etanercept-Methotrexate Therapy in Patients with Moderately Active Rheumatoid Arthritis
Background/Purpose: Active joint inflammation and structural damage in patients with rheumatoid arthritis (RA) often result in impaired physical function and ultimately work disability.1,2 Lost productivity…Abstract Number: 1209 • 2012 ACR/ARHP Annual Meeting
Functional Role of Chondrogenic Progenitor Cells in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease of still unknown etiology leading to progressive cartilage and bone destruction. Proinflammatory cytokines, immunoregulatory cells…Abstract Number: 413 • 2012 ACR/ARHP Annual Meeting
α(1,2)-Linked Fucosylated Cytokines Are Upregulated in Rheumatoid Arthritis
Background/Purpose: Glycosylation is a common post-translational modification of proteins in eukaryotes. Fucosylated glycans are synthesized by fucosyltransferases (futs). We previously reported that sialyl Lewisx, synthesized…
ACR Meeting Abstracts